Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 450

1.

Novel semisynthetic derivative of antibiotic Eremomycin active against drug-resistant gram-positive pathogens including Bacillus anthracis.

Maples KR, Wheeler C, Ip E, Plattner JJ, Chu D, Zhang YK, Preobrazhenskaya MN, Printsevskaya SS, Solovieva SE, Olsufyeva EN, Heine H, Lovchik J, Lyons CR.

J Med Chem. 2007 Jul 26;50(15):3681-5. Epub 2007 Jul 3.

PMID:
17608397
2.

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD.

Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9.

3.

Structure-activity relationships in the series of eremomycin carboxamides.

Miroshnikova OV, Printsevskaya SS, Olsufyeva EN, Pavlov AY, Nilius A, Hensey-Rudloff D, Preobrazhenskaya MN.

J Antibiot (Tokyo). 2000 Mar;53(3):286-93.

4.

Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Stratford RE, Cooper RD.

Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. Erratum in: Antimicrob Agents Chemother 1996 May;40(5):1330.

5.

N'-(alpha-aminoacyl)- and N'-alpha-(N-alkylamino)acyl derivatives of vancomycin and eremomycin. II. Antibacterial activity of N'-(alpha-aminoacyl)- and N'-alpha-(N-alkylamino)acyl derivatives of vancomycin and eremomycin.

Plattner JJ, Chu D, Mirchink EP, Isakova EB, Preobrazhenskaya MN, Olsufyeva EN, Miroshnikova OV, Printsevskaya SS.

J Antibiot (Tokyo). 2007 Apr;60(4):245-50.

PMID:
17456974
6.

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.

Goldstein BP, Candiani G, Arain TM, RomanĂ² G, Ciciliato I, Berti M, Abbondi M, Scotti R, Mainini M, Ripamonti F, et al.

Antimicrob Agents Chemother. 1995 Jul;39(7):1580-8.

7.

Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria.

Printsevskaya SS, Pavlov AY, Olsufyeva EN, Mirchink EP, Isakova EB, Reznikova MI, Goldman RC, Branstrom AA, Baizman ER, Longley CB, Sztaricskai F, Batta G, Preobrazhenskaya MN.

J Med Chem. 2002 Mar 14;45(6):1340-7.

PMID:
11882003
8.
9.

Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.

Printsevskaya SS, Solovieva SE, Olsufyeva EN, Mirchink EP, Isakova EB, De Clercq E, Balzarini J, Preobrazhenskaya MN.

J Med Chem. 2005 Jun 2;48(11):3885-90.

PMID:
15916441
10.

Helvecardins A and B, novel glycopeptide antibiotics. III. Biological properties.

Takeuchi M, Katayama T, Inukai M.

J Antibiot (Tokyo). 1991 Mar;44(3):278-81.

11.

Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.

Printsevskaya SS, Pavlov AY, Olsufyeva EN, Mirchink EP, Preobrazhenskaya MN.

J Med Chem. 2003 Mar 27;46(7):1204-9.

PMID:
12646030
12.

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.

13.

Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01.

Shao C, Zhou W, Zhang S, Wei W, Ruan L, Jin Y, Sun X, Huang Y.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6732-8. doi: 10.1016/j.bmcl.2011.09.045. Epub 2011 Sep 18.

PMID:
21978682
14.

A multivalent approach to drug discovery for novel antibiotics.

Long DD, Aggen JB, Christensen BG, Judice JK, Hegde SS, Kaniga K, Krause KM, Linsell MS, Moran EJ, Pace JL.

J Antibiot (Tokyo). 2008 Oct;61(10):595-602. doi: 10.1038/ja.2008.79.

PMID:
19168973
15.
16.

In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.

Brumfitt W, Hamilton-Miller JM, Shah S.

J Antimicrob Chemother. 1992 Jul;30 Suppl A:29-37.

PMID:
1399948
17.

Glycopeptide antibiotics: from conventional molecules to new derivatives.

Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM.

Drugs. 2004;64(9):913-36. Review.

PMID:
15101783
18.

Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.

Hirokawa Y, Kinoshita H, Tanaka T, Nakata K, Kitadai N, Fujimoto K, Kashimoto S, Kojima T, Kato S.

J Med Chem. 2008 Apr 10;51(7):1991-4. doi: 10.1021/jm8000136. Epub 2008 Mar 11.

PMID:
18330977
19.

Glycopeptides: Update on an old successful antibiotic class.

Pace JL, Yang G.

Biochem Pharmacol. 2006 Mar 30;71(7):968-80. Epub 2006 Jan 18. Review.

PMID:
16412985
20.

[New derivatives of eremomycin containing (15)n or f atoms for NMR study].

Solov'eva SE, Printsevskaia SS, Olsuf'eva EN, Batta G, Preobrazhenskaia MN.

Bioorg Khim. 2008 Nov-Dec;34(6):831-9. Russian.

PMID:
19088759

Supplemental Content

Support Center